CN108371709A - 黑枸杞肿瘤康复基因酶 - Google Patents
黑枸杞肿瘤康复基因酶 Download PDFInfo
- Publication number
- CN108371709A CN108371709A CN201810270032.1A CN201810270032A CN108371709A CN 108371709 A CN108371709 A CN 108371709A CN 201810270032 A CN201810270032 A CN 201810270032A CN 108371709 A CN108371709 A CN 108371709A
- Authority
- CN
- China
- Prior art keywords
- cancer
- lycium ruthenicum
- liver
- cell
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 76
- 241000169546 Lycium ruthenicum Species 0.000 title claims abstract description 42
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 34
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 29
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 27
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 26
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 26
- 235000006279 cobamamide Nutrition 0.000 claims description 22
- 239000011789 cobamamide Substances 0.000 claims description 22
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 claims description 22
- 229960005452 cobamamide Drugs 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 21
- 229920002444 Exopolysaccharide Polymers 0.000 claims description 17
- 239000004310 lactic acid Substances 0.000 claims description 17
- 235000014655 lactic acid Nutrition 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 235000020256 human milk Nutrition 0.000 claims description 14
- 210000004251 human milk Anatomy 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 45
- 210000004185 liver Anatomy 0.000 abstract description 29
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 17
- 230000036737 immune function Effects 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 11
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 230000002929 anti-fatigue Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 5
- 238000005728 strengthening Methods 0.000 abstract description 5
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 210000004072 lung Anatomy 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 238000011127 radiochemotherapy Methods 0.000 abstract description 3
- 206010010774 Constipation Diseases 0.000 abstract description 2
- 206010058046 Post procedural complication Diseases 0.000 abstract description 2
- 208000035965 Postoperative Complications Diseases 0.000 abstract description 2
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 230000000049 anti-anxiety effect Effects 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 239000002249 anxiolytic agent Substances 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 230000000955 neuroendocrine Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 230000003860 sleep quality Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 235000004554 glutamine Nutrition 0.000 description 29
- 230000006870 function Effects 0.000 description 24
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102100036774 Afamin Human genes 0.000 description 10
- 108010090535 alpha-albumin Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000002751 lymph Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000002019 anti-mutation Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920002414 procyanidin Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- OSOHBQZPFDDOMK-UHFFFAOYSA-N azane;propan-2-one Chemical compound N.CC(C)=O OSOHBQZPFDDOMK-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 230000002281 colonystimulating effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- BDCLDNALSPBWPQ-UHFFFAOYSA-N 3-oxohexanoic acid Chemical compound CCCC(=O)CC(O)=O BDCLDNALSPBWPQ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241001096899 Ferula ammoniacum Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- AKKNIFSFXKNCML-UHFFFAOYSA-N azanium;4-hydroxy-3,4-dioxobutanoate Chemical compound [NH4+].OC(=O)C(=O)CC([O-])=O AKKNIFSFXKNCML-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000292 leukogenic effect Effects 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
黑枸杞肿瘤康复基因酶属于高端特医食品,尤以青藏高原柴达木盆地天然无污染有机绿色优质黑枸杞萃取物等原料。该产品滋补肝肾、滋阴补肺、益气养血、健脾和胃、保肝护肝、改善内分泌、扶正固本、助消化、增加食欲、安神镇静、抗焦虑、抗辐射、抗疲劳、改善便秘、抗病毒、抗菌消炎、防癌抗癌。具有增强免疫功能,抑制化学性肝损伤、调理脾胃功能、调节神经内分泌、提高睡眠质量、减轻放化疗毒副作用和放化疗对组织器官的损伤、修复受损组织和恢复体能、改善患者临床症状、减少手术并发症,防止肿瘤复发与转移、提高患者生存质量和延缓生存期、综合营养辅助治疗恶性肿瘤、补虚和癌症术后康复等作用。
Description
一、技术领域:本发明属于高端特医食品,尤以青藏高原柴达木盆地天然无污染有机绿色优质黑枸杞萃取物等为原料制成的特医食品,采用现代最先进生物发酵技术和工艺加工而成。
二、背景技术:该发明以黑枸杞萃取物、母乳α-白蛋白(多肽核苷酸)、谷氨酰胺双肽、共轭亚油酸甘油酯(ω-3脂肪酸)、乳酸菌胞外多糖(酵母壁多糖)、腺苷钴胺等为原料制成的特医食品。该产品滋补肝肾、益气养血、健脾和胃、保肝护肝、扶正固本、助消化、增加食欲、安神镇静、抗焦虑、抗辐射、抗疲劳、改善便秘、抗病毒、抗菌消炎、防癌抗癌。目前市场上还没有本产品,创新研发该产品可为给肿瘤和癌症患者提供了一种辅助治疗和康复的新产品。该产品以纯天然药食两用植物和生物制品为原料,采用现代最新生物发酵技术和工艺制成的口服液,纯度高,生物活性强,吸收利用好,无任何毒副作用,服用方便,效果显著。
三、发明内容:关爱生命,科学防治癌症。癌症是人类的头号“杀手”,癌症的快速蔓延已引起全社会的关注。营养疗法对提高晚期癌症患者的生存质量,延长生命生存时间,提高放化疗耐受力和防化疗后快速复原,消除患者体内癌症发生,发展、转移复发等各种因素,防治转移复发具有极高的实用价值,是现有治疗癌症手段非常有效的补充,也是营养支持和干预效果的突破。癌症患者营养不良是我国恶性肿瘤常见的并发症之一。有统计数据显示,我国有63%肿瘤患者有营养不良症,26%的肿瘤患者死于营养不良。有效的营养支持和治疗是发达国家获得较高的治愈率显著的效果,这也是对癌症多学科综合治疗的一个极为重要的补充手段。这种独特理念创新,极高的效果实证,对造福更多的癌症患者。因此癌症的有效治疗需要营养的干预,创新研发这种新的癌症营养治疗产品,具有重要而深远的社会意义,也可造福人类。
四、原料配方:黑枸杞萃取物10-60千克、母乳α-白蛋白(多肽核苷酸)20-70千克、谷氨酰胺双肽10-50千克、共轭亚油酸甘油酯(ω-3脂肪酸)3-8千克、乳酸菌胞外多糖(酵母壁多糖)4-7千克、腺苷钴胺1-6克、辅料为原料。
五、技术方案:
(一)黑枸杞萃取物:(Lyciam barbarnm extraat),黑枸杞是生长在青藏高原绿色生态环境,纯天然珍品药食两用植物黑枸杞干燥果实。黑枸杞是一种稀有珍贵的原生态高端滋补品。黑枸杞为茄科植物枸杞成熟果实。性平,味甘。归肝、肾经。具有滋补肝肾、益精明目、润肺的功效。用于虚劳精亏、腰膝酸痛、眩晕耳鸣、内热消渴、血虚萎黄、提高视力、目昏不明等。现代医学研究认为,黑枸杞具有增强免疫力、抗疲劳、降血压、降血脂、降血糖、保护肝脏、减肥、抗衰老、抗癌等功能。
化学成分:黑枸杞含多糖、18种氨基酸(包括人体所必需8种氨基酸、精氨酸、半胱氨酸)、甜菜碱、胡萝卜素、维生素B、维生素C、烟酸等多种维生素以及锰、铬、锌、铜、镁、钙、锗、钴等微量元素。而且还有丰富的天然原花青素,其中原花青素含量是蓝莓含量的数倍,是迄今为止发现原花青素含量最高的天然野生植物。
药理作用:1、增强免疫力:小鼠灌服水提取物或肌注醇提取物均能显著增强其网状内皮系统对印度墨汁的吞噬能力。水提取物或枸杞多糖均能促进小鼠腹腔巨噬细胞吞噬功能和血清中溶菌酶活性。给正常或老年小鼠灌服或腹枸杞多糖,能显著增强腹腔巨噬细胞c3b和Fc的受体数和活力,可使老年小鼠抑制性T细胞调节抗体功能恢复到成年小鼠的水平。黑枸杞多糖纯品比粗品具有更显著的免疫应答效应,各项免疫指标(包括非特异性免疫的免疫器官质量、巨噬细胞吞噬作用、特异性体液免疫的血清溶血素,特异性细胞免疫中的退发型变态反应、淋巴细胞转化率、E玫瑰花结形成等)均有显著的差异。
2、保护肝脏、抗脂肪肝:黑枸杞萃取物对保护肝脏和抗脂肪肝具有一定的作用。现代医学研究发现,黑枸杞中含有一种有效成分-甜菜碱,它对治疗肝脏疾病很有效。实验表明,甜菜碱有抑制脂肪在肝细胞内沉积,促进肝细胞再生的作用。另外,黑枸杞的中甜菜碱能防止肝脏内过多的脂肪贮存,有防脂肪肝的作用,据报道,长期经大鼠饲喂水提取物或甜菜碱饲料对ccl4引起的肝损害有保护作用,能明显降低转氨酶及肝中脂质的变化,可抑制肝中脂质沉积及促进肝细胞新生,对肝脏脂质过氧化损伤有明显的保护作用。
3、抗氧化:黑枸杞具有良好的抗氧化作用。黑枸杞含有丰富的原花青素,能抑制血浆中的脂质过氧化自由基生成作用,又能阻断脂质过氧化作用。在保护DNA、蛋白质和膜结构免遭氧化损伤起着重要作用,已知人体晶状体、角膜及玻璃体中的超氧化物歧化酶活性低,老年人血浆和组织,这是一种维持机制减弱,可能是老年人血浆过氧化脂质含量增高以及易患白内障等疾病的重要原因之一,黑枸杞中的原花青素,具有强大的抗氧化作用,可以逆转这一过程。另据报道,黑枸杞中的原花青素,由于分子结构中有电子的羟基(酚基)部分,是由优良的氢或中子的给予体,有很强的抗氧化能力。在体内约为维生素E的50倍,为维生素C的20倍。据法国科学院的试验报告,认为原花青素是迄今为止所有发现最强、最有效的自由基清剂之一,尤其是在体内活性,是其他抗氧化剂不可比拟的。
4、抗应激:研究表明,电击加低剂量γ射线照射后大鼠的脾重指数明显降低,大脑皮层指数明显升高,脾和大脑层总脂含量明显降低,脂质过氧化产物丙二醛明显增加。腹腔注射黑枸杞萃取液可见给药组脾和脑匀浆总脂水平提近对照组,脾匀浆MDA含量显著降低,表明黑枸杞萃取物具有抗应激作用。
5、抗辐射、升高白细胞:黑枸杞萃取物能明显促进辐射损伤小鼠免疫功能的恢复,可使受辐射的小鼠胸腺指数、脾细胞的增殖反应等均明显增强。表明其对放射病的治疗有很好的作用,对60Co照射所致白细胞数降低有明显的升白作用。
6、对肿瘤放化疗增效和减毒作用:研究发现,黑枸杞萃取物对急性乏氧性肿瘤细胞具有很好的放疗增效作用,对机体无明显毒副作用。在使用C57BL纯小鼠及可移植性肺癌模型实验发现,LBP结合放疗显示出明显的放疗增效作用;对急性乏氧性肿瘤细胞也有一定的放疗增效作用,且对机体还有减毒作用。
7、调节神经内分泌:黑枸杞在常用剂量可明显增高脾重指数及淋巴细胞增殖反应,并使脾去甲肾上腺素(NA)含量下降。该作用是通过下丘脑NA含量下降,同时通过下丘脑-垂体-肾上腺轴(HPA)调动血浆皮质酮参加免疫应答而实现的。
8、促进造血:黑枸杞可使正常小鼠骨髓中爆式红系集落形成单位和红系集落形成单位上升;能促进小鼠脾脏T淋巴细胞分泌集落刺激因子,提高小鼠血清集落刺激活性水平;在体内外培养体系中,黑枸杞可加强集落刺激因子的集落刺激活性。另外,黑枸杞还可促进正常小鼠骨髓造血干细胞向粒子分化,具有促进骨髓造血的功能。
9、抗突变:黑枸杞有抗丝裂霉(MMC)诱发姐妹染色体,单体互换作用,能提高DNA损伤后的修复能力,降低姐妹染色单体频率,对抗遗传损伤。黑枸杞还能促进淋巴细胞的正常增殖周期和丝裂霉影响的增殖活力。表明黑枸杞对维护细胞正常发育,提高DNA修复能力和促进衰老细胞的年轻化方向逆转都有一定作用。近年来研究表明,黑枸杞具抗基因突变的作用,以防肿瘤的发生。
10、抗癌抗肿瘤:研究表明,黑枸杞具有很好的抗肿瘤作用,可促进肿瘤细胞死亡。黑枸杞萃取物即可以预防和减少体内细胞癌变,又可保障人体生殖细胞和胚胎细胞的正常生长,减少遗传疾病器官畸形的生长;即可控制癌灶发展,抑制肿瘤生长,又对肿瘤放射治疗有明显的增效和保护作用;还可提高和保护放射患者的免疫功能。与化疗联用还能增效减毒。另有研究,黑枸杞含有丰富的原花青素,可以通过相关酶的活性抑制癌变发生。有研究发现,原花青素具有显著的抗癌功效,在抑制肿瘤转移作用于癌细胞的生长周期,诱导凋亡,抑制增殖。另外原花青素还能通过切断癌细胞所需的血液供给,阻止癌细胞扩散。据国内报道,黑枸杞含有丰富的原花青素,对乳腺癌具有防治作用。用黑枸杞在花青素能降低乳腺癌裸鼠和淋巴的转移率,降低裸鼠异种移植瘤血管生成及表达,从而抑制肿瘤血管生成,促进肿瘤凋亡,具有显著的抗肿瘤功效。
(二)母乳α-白蛋白(Breast milka al6cunmina)是从母乳中提取的一种功能大分子蛋白质,是人体不可或缺的营养物质,是目前发现最优质的蛋白质,可替代其他蛋白质对机体疾病进行防治。研究表明,母乳α-白蛋白可促进蛋白质、酶、荷尔蒙的调控。是沟通细胞间、器官信息的重要化学信使。具有防癌抗癌,为免疫系统制造对抗细胞和感染的抗体,提高免疫功能、抗病毒感染、促进造血功能、改善贫血、防止血小板聚集、提高血红细胞载氧能力、恢复肝脏功能,帮助创口血液凝固、促进创口愈合、修复细胞、改善细胞代谢、防止细胞变异,还可改善消化系统和慢性肠道疾病等功效。
生物学功能:1、抗癌防治肿瘤:人类基因组稳定维持是一切生命活动的基础,细胞通过不断的分裂来修复和替换受损组织。最新研究表明,母乳α-白蛋白是一种非常重要的营养物质,可作为抗肿瘤药物的载体,显著提高肿瘤细胞中药物的分布,增强抗肿瘤药物的靶向性,为潜在的癌症治疗新靶点。通过大量的生物活性功能和临床前的实验显示,母乳α-白蛋白能直接高效杀死癌细胞。另据国外报道,瑞典隆德大学免疫学教授卡塔琳娜、斯万堡,一项最新研究发现,母乳α-白蛋白中含有一种“哈姆雷特”的化合物能杀死癌细胞更有效。这项新研究的人员介绍说,含有α-白蛋白的母乳会在胃里变成抗癌剂,它能够避开癌细胞外层防御,攻击线粒体和细胞核,通过使癌细胞失去能量来源,从而使癌细胞衰弱和死亡。
2、提高免疫功能:研究显示,母乳α-白蛋白对机体细胞免疫具有增强作用,可提高核酸及分解产物的吸收和提高免疫器官的分布,有助于免疫细胞内核酸代谢的补救合成,增强机体的细胞免疫功能。另外,母乳α-白蛋白还可促进免疫组织的功能恢复,修复胸腺、脾、淋巴等功能,提高集体抗病能力。
另外,母乳α-白蛋白还具有抗病毒、抗突变、恢复肝功能、促进造血、改善贫血、促进消化、促进伤口愈合等功效。
(三)谷氨酰胺双肽(Aiany-giutamine,ALN-GKN),是由玉米蛋白经酶解后产生的一种双肽,广泛参与机体各种生物活动,具有多种生物学功能。谷氨酰胺双肽是肾脏中氨合成和肝脏中尿素合成氨的载体,是细胞胺清除剂和生物合成许多重要物质,如核酸和氨基酸的共体。谷氨酰胺作为人体一种氨基酸在调节人体蛋白质合成,抑制蛋白质降解,刺激细胞生长,激活免疫功能,促进激素分泌,改善脑功能、防止酒精中毒、保护肝脏、抗抑郁、提高免疫力、抗疲劳、阻止肌肉老化、抗衰老、治愈消化器官溃疡等功能起着极其重要的作用。
生理功能:1、营养功能:谷氨酰胺双肽虽然是一种非必需氨基酸,在人体内可自行合成,但却是人体中含量较多的一种氨基酸,如在肌肉蛋白中约占氨基酸总量的61%,在血浆中约占总游离氨基酸的20%。有人在培养哺乳动物细胞培养液中,发现最适宜于细胞生长的各种氨基酸中,谷氨酰胺双肽是需要量是最高的,可见其在细胞增生中的重要性。谷氨酰胺双肽的碳链骨架可在肝脏中转变成葡萄糖,也可提供碳链骨架而与α-氨基酸合成其他氨基酸,而谷氨酰胺双肽则可作为合成核苷酸,氨基酸和胺糖的氨源,因此是合成蛋白质的基本构架单位。在代谢过程中是氨基酸的运输工具,在肾脏、肝脏、消化道等器官间起着重要的氨、尿素、氨等的转换功能。
2、增强免疫功能:研究表明,谷氨酰胺双肽具有极强的免疫调节作用,它是淋巴细胞分泌、增殖及其功能维持所必需的物质。作为核酸生命合成的前体和主要能源,谷氨酰胺双肽可促进淋巴细胞、巨噬细胞的有丝分裂和分化增殖,增加细胞因子TNF、IL-1等的产生和磷脂的mRNA合成,提供外源性谷氨酰胺双肽可明显增加危重病人的淋巴细胞总数、T淋巴细胞和循环中CD4/CD8的比率。具有显著的增强免疫功能作用。
3、抗炎:研究表明,机体在炎性过程中会分泌许多细胞因子进入血液循环,其中NF-KB可以被一些因子激活、如IL-1、TNF-α等,一旦被激活NF-KB就可以通过调节细胞基因,影响机体的免疫状态和炎性反应,激活的NF-KB数量与黏膜炎性病变的程度密切相关,谷氨酰胺双肽可减少NF-KB的表达,维持重症炎症病人的肠道通透性,降低肠道细菌易拉的发生,抑制炎性因子的释放,减轻机体应急反应程度,从而有效抑制炎性病变。
4、减轻放化疗症状:一项针对谷氨酰胺双肽在腹腔和盆腔癌放射治疗中的临床应用,32例患者在放化疗期间口服谷氨酰胺双肽,直至放化疗结束后4个星期26例患者没有接受谷氨酰胺双肽治疗,结果表明,谷氨酰胺双肽治疗组的急性腹泻和慢性腹泻发生率分别为28%和3.8%,未使用谷氨酰胺治疗组发生率分别为61%和15.6%。由此可见,谷氨酰胺双肽具有明显的胃肠黏膜保护作用。因此,谷氨酰胺双肽能明见降低妇科恶性肿瘤患者后急性肠道反应程度和肠道黏膜损伤。
5、保护胃肠道黏膜:谷氨酰胺双肽对胃肠道黏膜有积极的营养和保护作用。谷氨酰胺双肽是胃肠道的主要能源和蛋白质的氮源供体,胃黏膜重量、DNA和蛋白质含量的增加具有很好的作用,因此,谷氨酰胺双肽具有保护胃肠黏膜的功效。
6、保肝护肝:谷氨酰胺双肽具有保护肝脏组织的特殊功能。它可以防止由于过量摄入碳水化合物导致的脂肪肝,可刺激胰高血糖素分泌,从而降低动脉胰岛素/血糖素的比例,增加肝脏脂类的运出。谷氨酰胺双肽还有一个特殊的功能,它可以增加机体内乙醇脱氢酶的含量,从而快速分解乙醇,加快酒精的分解,治疗和预防酒精中毒,保护肝脏。
7、抗疲劳:谷氨酰胺双肽具有独特的功能和营养特性,因此谷氨酰胺双肽可用于治疗运动员综合症,恢复高强度劳动和运动后的疲劳。研究证实,谷氨酰胺是肌肉和血浆中最为丰富的氨基酸,它为白细胞快速提供能量,同时也是合成核苷酸的重要原料。外源性补充谷氨酰胺双肽有助于维持运动员正常血液中的谷氨酰胺双肽的浓度,并可以预防长时间运动后免疫功能的损害,还有研究表明,马拉松运动后2小时口服谷氨酰胺双肽能减少运动损伤。
此外,谷氨酰胺双肽还可以抑制腹泻,减少电解质和水分丢失。
(四)共轭亚油酸甘油酯(CLAG),共轭亚油酸是存在于反刍动物牛、羊的乳脂及肉制品中一种天然的脂肪酸。是由脂肪酸-亚油酸衍生的共轭双键的多种位置和几何异物体的总称,即是亚油酸9,12-18∶2的项生衍生物。它含有大约等量的C9,t11和t10,c12,两种异构体被证实具有很强的生理活性。据国外大量的研究证实,共轭亚油酸具有多种生物学功能:减肥、降血脂、防治糖尿病、防癌抗癌、防治心血管疾病、增强免疫功能、抗氧化等功效。
药理作用:1.保护肝脏:研究表明,共轭亚油酸甘油酯对肝功能具有显著的保护作用。其作用机理,可减少炎症因子的释放,减轻肝细胞炎症性损伤;稳定肝细胞膜,减少肝细胞进一步的破坏;增加肝细胞膜流动性并改善其生理功能,促使肝细胞代谢功能尽快恢复;增加肝脏血液灌注,改善肝脏微循环。维持肝细胞代谢并促进肝细胞参与全身的代谢。
2、防治癌症:最新研究表明,共轭亚油酸甘油酯具有抑制基因突变的作用。摄入共轭亚油酸甘油酯能明显降低突变细胞从血液中吸收营养,切断其营养供给,故能有效预防癌细胞突变的发生。另外,共轭亚油酸甘油酯会使引发癌症的酶失去活性,还会在细胞膜上再形成一层保护膜,能够阻止细胞表面粘连分子形成,致使癌细胞无法粘附到细胞膜上,故将预防癌症的发生。进一步的研究发现,共轭亚油酸甘油酯抗癌作用机制包括抑制癌细胞增殖和凋亡信号和转导,降低癌细胞内环氧酶的活性;诱导癌细胞自噬,抑制癌细胞新生血管生成,具有显著防治癌症作用。另据报道,共轭亚油酸甘油酯具有抑制肿癌细胞生长,减少正常细胞的癌变生理作用和癌症转移。它还能显著降低胃癌、前列腺癌、乳腺癌、皮肤癌等多种癌症的发病率。其抗癌作用包括:(1)抑制化学致癌剂与DNA附加体的形成;(2)、抑制细胞素LTB4及内毒素等的产生;(3)增强免疫力;(4)抑制持有激素受体的癌细胞增殖。另有报道,大量的动物模型和人体癌细胞体外培养模型实验发现,共轭亚油酸在发展的各阶段均有抑制作用。其抑制癌症包括开始阶段、发展和转移阶段,甚至是癌症的发展全过程。及乌氨酸脱羧酶和蛋激酶C等酶的活性,以及抑制癌细胞蛋白质和核酸的形成。
3、、提高癌症患者生存率:最新研究发现,癌症患者服用ω-3脂肪酸可显著提高癌症患者的生存率。研究调查了1000多名结直肠癌患者的资料,经分析发现,在确诊为结直肠癌后,每天至少服用0.3克共轭亚油酸甘油酯的人,因结直肠癌死亡的可能性比每天服用不足0.1克的人生存率低41%。其作用机制为共轭亚油酸甘油酯可遏制癌细胞的增殖、转移和扩散。
4、防治心血管疾病:共轭亚油酸甘油酯具有降低胆固醇、甘油三脂和低密度脂蛋白的作用。其代谢产物具有抗凝血和扩张血管,增加血管弹性,抑制血小板聚集,具有防治心血管病的作用。据国外报道,美国研究人员对近8万名女性长达16年的跟踪研究证实,经常食用ω-3脂肪酸的女性与基本不食用的女性相比,其心脏功能衰竭和冠状动脉疾病所导致的死亡风险可减少46%,心脏病衰竭的猝死风险降低为68%。
5、抗炎:共轭亚油酸甘油酯对各种炎症和细胞因子有抑制作用,能减少炎症因子的生成。另有报道,共轭亚油酸甘油酯具有良好的抗炎作用,有实验发现,风湿性关节炎患者摄入共轭亚油酸甘油酯后可以完全停止服用非类固醇抗炎药物。另有部分可将非固醇抗炎药物减半。
6、增强免疫功能:共轭亚油酸甘油酯有助于强化免疫系统,在人体免疫系统中必需脂肪酸,能保护基因免受损害,对增强人体免疫力,提高人体抵抗力具有重要的作用。有研究发现,共轭亚油酸甘油酯可影响细胞膜结构的完整性、稳定性和流动性,影响细胞运动,受体形成受腰带与配体的结合等,从而减少细胞因子的产生和释放,改善肺、肝脏、肠的血供和氧代谢。因此,共轭亚油酸甘油酯在细胞水平诱导的改变较为持久,是有效的免疫调节营养素。
7、抗氧化:研究发现,共轭亚油酸甘油酯能延缓人体衰老的进程。成年人服用共轭亚油酸甘油酯有助于改善体脂肪比例,在一定程度上对“端粒”(染色体、端粒位上的丝点,其主要功能是保持基因的稳定状态)有益,人体中的脂肪比例越低端粒就越长,对健康越有益。研究还发现,共轭亚油酸甘油酯能将血液中的自由基对人体造成的损害降低15%,另外,共轭亚油酸甘油酯还能降低人体内白细胞介素6的含量和人体内炎症水平。
(五)乳酸菌胞外多糖(Exopolysaccharides,EPS),是由细菌、真菌和蓝绿藻产生的一种高分子量的化合物,也是一种生物源生物活性成分。是微生物生长代谢过程种重要的次生代谢产物,具有广泛的医疗保健作用。
生物学功效:1、调节免疫力:最新研究证实,乳酸菌胞外多糖及其成份,如脂多糖,肽聚糖等,能激活机体免疫系统中的巨噬细胞,促进T、B淋巴细胞增殖,增强NK细胞吞噬作用活性,促进抗体生成等细胞免疫功效,从而发挥免疫调节活性作用。另外,乳酸菌胞外多糖还能促进抗肿瘤细胞因子IL-6和TNF-α等成分。
2、抗炎:乳酸菌胞外多糖所含的双链RNA的数量。研究发现,乳酸菌胞外多糖进入的树突状细胞后,会促进微生物产生大量的β干扰素,从而抑制肠道炎症。
3、防癌抗癌:最新研究表明,乳酸菌胞外多糖可抑制腐败菌的繁殖从而减少粪便中致癌物质,降低粪便中的腐败菌产生的致癌源合成酶,从而降低粪中致癌物质的生成。进一步研究发现,乳酸菌胞外多糖及通过刺激肠道黏膜淋巴结,激发免疫细胞活性,产生特异性抗体和致敏淋巴细胞,调节机体的免疫应答,刺激免疫系统使具攻击癌细胞。另外,乳酸菌胞外多糖及其表面分子可通过肿瘤细胞调节相关的基因表达而诱导肿瘤凋亡,从而抑制肿瘤的生长。另有报道,乳酸菌胞外多糖可产生NAD氧化还原酶、超氧化物歧化酶等活性成分,有助于增强机体抗癌能力,促进癌细胞自行凋亡。
4、保护肝脏:乳酸菌胞外多糖可减少有毒代谢物的形成。人体肠道内有害菌的产生并释放毒素进入血液中,对肝脏会产生严重的损伤。乳酸菌胞外多糖还可抑制产生毒素有害菌的数量,从而对肝病会产生严重的防治作用。另有报道,国内数家医院对378例慢性肝炎患者8周治疗,发现患者肝功能明显改善。另外,乳酸菌胞外多糖还可用于治疗肝昏迷,并可抑制乙肝病毒,促进大、小三阳转阴。
另外,乳酸菌胞外多糖还具有抗突变,促进消化、调节肠胃功能、改善肠道菌群。
(六)、腺苷钴胺(cobamamide forlnjection),又称腺苷辅酶,是维生素B12的活性辅酶形式之一。腺苷钴胺是从哺乳动物的组织中分离出一种生物化合物,可作为人体内酶的辅助因子。最新研究发现,腺苷钴胺可治疗恶性贫血、癌症、肝病、慢性胃缩性胃炎、抗病毒、促进消化吸收等多种功效。也可用于营养性疾患以及放射线和药物引起的白细胞减少症的治疗。
生物功能:1、抗病毒:研究发现,腺苷钴胺在体外能阻止细胞被HIV-I病毒感染,因此,腺苷钴胺在体外有抗HIV-I感染的作用。实验结果显示;腺苷钴胺能抑制逆转氯酶,从而阻止病毒RNA逆转录为DNA(DNA再与人类基因结合);抑制正常人体的单核巨噬细胞和淋巴细胞被HIV-I感染,抑制肿瘤坏死因子α的产生。因此,腺苷钴胺能有效治疗HIV-I病毒感染。
2、抗癌抗肿瘤:最新研究发现,腺苷钴胺是一种含钴有氰酸化合物,在其分解酶的作用下可分解为氰酸和苯甲醛,氰酸有毒能杀灭癌细胞,苯甲醛也具有很强的抗癌作用,对氨基苯甲酸能抗多种癌症。
3、治疗肝病:有临床研究证实,患有慢性肝病和肺结核的患者每天补充适量的腺苷钴胺,3个月后,体重和饮食得到改善。对29名病毒性肝炎患者使用腺苷钴胺,结果显示,在全血胆红素、血清谷氨草酰乙酸转氨酶、血清谷氨丙酮转氨酶及碱性磷酸酶的数值标准化方面,腺苷钴胺比氰钴胺更有效。在治疗各种急性肝病,可有效改善血清谷氨草酰乙酸转氨酶和血清谷氨丙酮较氨酶及碱性磷酸酶及全血胆红素数值。因此,腺苷钴胺对肝病有较好的治疗效果。
4、治疗贫血:腺苷钴胺缺乏会导致血液病,包括贫血、白血病、血小板减少形成巨噬细胞。腺苷钴胺存在于细胞线粒体内直接参与血红素的合成,促进红细胞发育和成熟,可提高体内血红蛋白含量。研究表明,在急性失血时,腺苷钴胺可增强骨髓细胞的增值活性,具有生血补血的作用。
5、改善睡眠:研究发现,缺乏腺苷钴胺会导致神经功能紊乱、抑郁睡眠质量差,记忆力下降等症状。一项新研究发现,慢性失眠患者服用腺苷钴胺后,有86%的人睡眠得到改善。
另外,腺苷钴胺还可用于放化疗引起的白细胞减少的治疗。
综上所述,该产品具有增强免疫功能,抑制化学性肝损伤、调理脾胃功能、提高睡眠质量、减轻放化疗毒副作用和放化疗对组织器官的损伤、修复受损组织和恢复体能、改善患者临床症状、防止白细胞减少、抑制肿瘤血管内皮细胞增殖和新生血管生成、从而控制和杀伤肿瘤细胞、减少手术并发症,防止肿瘤复发与转移、提高患者生存质量和延缓生存期、综合营养辅助治疗恶性肿瘤、补虚和癌症术后康复等作用。
六、制作工艺:
1、原料混合:将配方中的原料按物理特性进行混合。
2、搅拌:将混合后的原料送入搅拌机充分搅拌均匀。
3、溶化:将搅拌均匀的原料送入熔化罐加入纯化水溶化。
4、过滤:将溶解后的溶液送入过滤机过滤。
5、灌装封盖:将过滤后的溶液送入灌装机,灌装并封盖。
6、杀菌:将灌装后的溶液,投入85度-95度水中杀菌20分钟。
7、检验包装:将杀菌后的半成品,检验合格,包装为成品。
七、质量标准:
1、理化指标:
2、服用方法:每日3次,每次服用量20-30ml。
3、适应人群:适用于各肿瘤患者临床治疗和放化疗、术后康复及恶性肿瘤后期不能手术的患者辅助治疗等作用。
八、实施例:取黑枸杞萃取物10-60千克、母乳α-白蛋白(多肽核苷酸)20-70千克、谷氨酰胺双肽10-50千克、共轭亚油酸甘油酯(-3脂肪酸)3-8千克、乳酸菌胞外多糖(酵母壁多糖)4-7千克、腺苷钴胺1-6克、辅料为原料。经过将以上原料混合,充分搅拌均匀,送入熔化罐加入纯化水溶化后过滤,灌装封盖,在85-95度杀菌20分钟,检验合格,包装为成品。
Claims (1)
1.黑枸杞肿瘤康复基因酶制作工艺,其特征为:黑枸杞萃取物10-60千克、母乳α-白蛋白(多肽核苷酸)20-70千克、谷氨酰胺双肽10-50千克、共轭亚油酸甘油酯(-3脂肪酸)3-8千克、乳酸菌胞外多糖(酵母壁多糖)4-7千克、腺苷钴胺1-6克、辅料为原料。经过将以上原料混合,充分搅拌均匀,送入熔化罐加入纯化水溶化后过滤,灌装封盖,在85-95度杀菌20分钟检验合格,包装为成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810270032.1A CN108371709A (zh) | 2018-03-29 | 2018-03-29 | 黑枸杞肿瘤康复基因酶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810270032.1A CN108371709A (zh) | 2018-03-29 | 2018-03-29 | 黑枸杞肿瘤康复基因酶 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108371709A true CN108371709A (zh) | 2018-08-07 |
Family
ID=63031827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810270032.1A Pending CN108371709A (zh) | 2018-03-29 | 2018-03-29 | 黑枸杞肿瘤康复基因酶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108371709A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108902977A (zh) * | 2018-08-20 | 2018-11-30 | 苟春虎 | 黑藜麦肿瘤愈病康复营养肽 |
CN109198648A (zh) * | 2018-08-20 | 2019-01-15 | 苟春虎 | 金虫癌症救星基酶肽 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505144A (ja) * | 2003-09-10 | 2007-03-08 | インフラブロック・ファーマシューティカルス・インコーポレーテッド | 抗腫瘍療法のためのコバラミン結合体 |
CN102379851A (zh) * | 2010-09-03 | 2012-03-21 | 华北制药股份有限公司 | 一种注射用腺苷钴胺冻干制剂的制备方法 |
CN102526698A (zh) * | 2012-01-05 | 2012-07-04 | 苟春虎 | 虫草多肽氨基酸营养液 |
CN106174580A (zh) * | 2016-08-29 | 2016-12-07 | 苟春虎 | 黑枸杞降血糖防并发症片 |
WO2017053328A1 (en) * | 2015-09-21 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nutritional treatment for cancer |
CN106668811A (zh) * | 2016-12-20 | 2017-05-17 | 苟春虎 | 黑枸杞抗癌救生片 |
-
2018
- 2018-03-29 CN CN201810270032.1A patent/CN108371709A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505144A (ja) * | 2003-09-10 | 2007-03-08 | インフラブロック・ファーマシューティカルス・インコーポレーテッド | 抗腫瘍療法のためのコバラミン結合体 |
CN102379851A (zh) * | 2010-09-03 | 2012-03-21 | 华北制药股份有限公司 | 一种注射用腺苷钴胺冻干制剂的制备方法 |
CN102526698A (zh) * | 2012-01-05 | 2012-07-04 | 苟春虎 | 虫草多肽氨基酸营养液 |
WO2017053328A1 (en) * | 2015-09-21 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nutritional treatment for cancer |
CN106174580A (zh) * | 2016-08-29 | 2016-12-07 | 苟春虎 | 黑枸杞降血糖防并发症片 |
CN106668811A (zh) * | 2016-12-20 | 2017-05-17 | 苟春虎 | 黑枸杞抗癌救生片 |
Non-Patent Citations (7)
Title |
---|
廉新慧等: "三种多糖对小鼠免疫功能的影响", 《动物医学进展》 * |
张明等: "牛α乳白蛋白-亚油酸复合物的结构及抗肿瘤活性", 《光谱学与光谱分析》 * |
景俊杰等: "谷氨酰胺双肽与临床应用", 《中国医学创新》 * |
杨斌等: "黑枸杞及其功能性成分在食品工业中的应用及开发进展", 《轻工科技》 * |
梁增澜等: "乳酸菌胞外多糖免疫活性的研究进展", 《食品与发酵工业》 * |
王志良等: "腺苷钴胺的临床应用进展", 《中国药事》 * |
田玉霞等: "共轭亚油酸甘油酯的研究进展", 《中国油脂》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108902977A (zh) * | 2018-08-20 | 2018-11-30 | 苟春虎 | 黑藜麦肿瘤愈病康复营养肽 |
CN109198648A (zh) * | 2018-08-20 | 2019-01-15 | 苟春虎 | 金虫癌症救星基酶肽 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101473953B (zh) | 净血排毒组合食品及其加工方法和应用 | |
CN104366480A (zh) | 一种减肥降脂营养代餐粉及其制备方法 | |
KR101539382B1 (ko) | 장 기능 개선 및 배변 촉진용 식품 조성물 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN105815514A (zh) | 藜麦减肥奶茶 | |
CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
CN103190483A (zh) | 儿童成长奶茶 | |
CN102160664A (zh) | 儿童营养饮料 | |
CN102526445A (zh) | 一种增强免疫力、缓解体力疲劳、抗肿瘤功能的保健药物配方 | |
JP2016102111A (ja) | 補助化療薬品とされる医薬組成物その用途 | |
JP6626035B2 (ja) | 筋肉減少症の予防または治療用薬学組成物及び予防または改善用健康機能食品組成物 | |
CN104757535A (zh) | 黑枸杞减肥片(茶) | |
CN108371709A (zh) | 黑枸杞肿瘤康复基因酶 | |
WO2008095093A2 (en) | Method of increasing cellular function and health of glutathione deficient animals | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
CN104940241B (zh) | 一种防治妇女更年期综合征的硒虫草复方制剂 | |
CN106174286A (zh) | 高级金枸杞营养果酱 | |
CN114617267A (zh) | 一种强化型复合骨肽及其制备方法与应用 | |
CN114868890A (zh) | 一种适用肿瘤患者多维营养素配方 | |
CN103330118A (zh) | 减肥药物 | |
CN109198648A (zh) | 金虫癌症救星基酶肽 | |
CN101869329B (zh) | 延年益寿防癌保健饮料 | |
CN107970437A (zh) | 虫草克癌基因肽 | |
CN107259530A (zh) | 一种用于安神、改善睡眠的百香果配方食品 | |
CN108652010B (zh) | 一种欧米伽3速溶剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Gou Chunhu Document name: Notice of completion of reexamination case |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180807 |